Research Topics
Genomes and GenesSpecies | Andrew BerchuckSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrenceLaura J Havrilesky
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 110:374-82. 2008....- Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarraysAndrew Berchuck
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Am J Obstet Gynecol 190:910-25. 2004..The purpose of this study was to define gene expression patterns that are associated with the optimal versus suboptimal debulking of advanced-stage serous ovarian cancers... - Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck
Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
Cancer Epidemiol Biomarkers Prev 13:2141-7. 2004..In this study, we sought to determine whether this polymorphism affects ovarian cancer risk... - Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancersAndrew Berchuck
Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Institute of Statistics and Decision Sciences, Center for Applied Genomics and Technology, Duke University Medical Center, Durham, North Carolina, USA
Clin Cancer Res 11:3686-96. 2005..The objective of this study was to define gene expression patterns associated with favorable survival... - Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortiumAndrew Berchuck
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Adv Exp Med Biol 622:53-67. 2008 - Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcomeAndrew Berchuck
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 15:2448-55. 2009..In the present study, we report on gene expression of early-stage cancers and validate our prognostic model for advanced-stage cancers... - Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancerPaula S Lee
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
Int J Cancer 126:1378-89. 2010..04). MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer... - Expression signatures of TP53 mutations in serous ovarian cancersMarcus Q Bernardini
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, 600 University Avenue, Toronto, Ontario M5G2M9, Canada
BMC Cancer 10:237. 2010..Mutations in the TP53 gene are extremely common and occur very early in the progression of serous ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and biology of the disease... - Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancerJason C Barnett
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC
Am J Obstet Gynecol 205:143.e1-6. 2011..The objective of the study was to compare adverse event rates between laparoscopic vs open surgery for endometrial cancer... - Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancerRobert M Wenham
Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Soc Gynecol Investig 10:381-7. 2003..The 2G allele also has been associated with increased MMP1 expression. We investigated the relationship between the MMP1 polymorphism and ovarian cancer risk in a large population-based, case-control study... - The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancerAngeles Alvarez Secord
Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
Gynecol Oncol 107:285-91. 2007..We sought to determine the outcome of patients with advanced stage endometrial cancer treated with postoperative chemotherapy+/-radiation to determine whether there was an advantage to combining treatment modalities... - Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group studyJennifer M Rubatt
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 112:469-74. 2009..The aims of this study were to examine prognostic significance of microvessel density (MVD) in previously-untreated, advanced epithelial ovarian cancer (EOC) and explore associations between MVD and factors that affect angiogenesis... - Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancerJoellen M Schildkraut
Department of Community and Family Medicine, Duke University Medical Center, Box 2949, Durham, NC 27710, USA
Cancer Epidemiol Biomarkers Prev 16:473-80. 2007..Two trinucleotide repeat polymorphisms have been described in exon 1 of the androgen receptor (AR) gene that may affect its function. Previous studies of ovarian cancer and AR repeat polymorphisms have been inconsistent... - Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancerRobert M Wenham
Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 9:4396-403. 2003..We have examined whether BRCA2 N372H or common amino acid-changing polymorphisms in BRCA1 predispose to ovarian cancer... - Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancerAngeles Alvarez Secord
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 3079, Duke University Medical Center, Durham, NC 27710, USA
Int J Clin Oncol 12:31-6. 2007..The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies... - Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinomaEllen Jones
Department of Radiation Oncology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Int J Hyperthermia 22:161-72. 2006..These promising results suggest a role for the use of adjuvant whole abdomen hyperthermia as a means of augmenting chemosensitization... - Yin yang 1 modulates taxane response in epithelial ovarian cancerNoriomi Matsumura
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
Mol Cancer Res 7:210-20. 2009.... - Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal womenPatricia G Moorman
Department of Community and Family Medicine, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, NC 27705, USA
Am J Epidemiol 167:1059-69. 2008..Findings suggest that associations between ovarian cancer and reproductive characteristics vary by menopausal status. Additional research is needed to further elucidate risk factors for postmenopausal disease... - The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancerLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
Gynecol Oncol 104:401-5. 2007..We sought to determine whether recurrence and survival of patients with stage IIIA endometrial cancer differ with surgical pathologic findings (positive peritoneal cytology versus positive adnexae or serosa) and adjuvant treatment... - Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group studyAngeles Alvarez Secord
Box 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 101:390-7. 2006..This study examined MASPIN expression in human ovarian cancer, and explored the association between MASPIN and prognosis in patients with advanced stage disease treated with first-line cisplatin, carboplatin and/or paclitaxel... - Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomasJay E Allard
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and the United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC, USA
Gynecol Oncol 107:52-7. 2007..Since FOLR1 overexpression is a frequent event in some types of endometrial carcinoma, we examined the relationship between FOLR1 overexpression and clinical and pathologic features to determine its prognostic relevance... - Gene expression patterns that characterize advanced stage serous ovarian cancersJohnathan M Lancaster
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Soc Gynecol Investig 11:51-9. 2004..With the generation of newer arrays with more transcripts, larger studies are possible to fully characterize genetic signatures that predict survival that may ultimately be used to guide therapeutic decision-making... - Association between DNA damage response and repair genes and risk of invasive serous ovarian cancerJoellen M Schildkraut
Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
PLoS ONE 5:e10061. 2010.... - Regulation of the metastasis suppressor gene MKK4 in ovarian cancerMonique A Spillman
Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
Gynecol Oncol 105:312-20. 2007..We sought to investigate whether promoter methylation, loss of heterozygosity, or changes in phosphorylation are involved in MKK4 dysregulation during ovarian carcinogenesis... - Resection of lymph node metastases influences survival in stage IIIC endometrial cancerLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
Gynecol Oncol 99:689-95. 2005..Our objective was to compare survival of patients who underwent resection of grossly positive lymph nodes (LN) to those with microscopically positive LN... - Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group sElizabeth L Jewell
Duke University Medical Center 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 115:424-9. 2009.... - Targeting slow-proliferating ovarian cancer cellsEiji Kondoh
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University, Durham, NC 27708, USA
Int J Cancer 126:2448-56. 2010..002; overall survival, p = 0.04). These results suggest that targeting quiescent ovarian cancer cells may be a worthwhile therapeutic approach to improving survival of women with ovarian cancer... - Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroupJoellen M Schildkraut
Department of Community and Family Medicine, Duke University Medical Center, Box 2949, Durham, NC 27710, USA
Cancer Epidemiol Biomarkers Prev 17:585-93. 2008..The objective of this study was to determine whether cyclin E overexpression defines an etiologically distinct subgroup of ovarian cancer... - Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer riskMonique A Spillman
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University, DUMC Box 3079, Durham, NC 27710, USA
Gynecol Oncol 97:543-9. 2005..It has been suggested that the 6A allele of the type I TGFbeta receptor (TGFbetaR1) polyalanine repeat tract polymorphism may increase susceptibility to various types of cancer including ovarian cancer... - Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancerNoriomi Matsumura
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Genome Res 21:74-82. 2011..These data suggest that accumulation of age-related epigenetic modifications leads to suppression of TGF-beta signaling and contributes to ovarian carcinogenesis... - Oncogenic pathway signatures in human cancers as a guide to targeted therapiesAndrea H Bild
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
Nature 439:353-7. 2006..Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics... - Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancerJaniel M Cragun
Duke University Medical Center, Box 3079, Durham, NC 27710, USA
J Clin Oncol 23:3668-75. 2005..CONCLUSION: These data add to the literature documenting the possible therapeutic benefit of selective lymphadenectomy in management of patients with apparent early-stage endometrial cancer... - No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North CarolinaJohnathan M Lancaster
Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Epidemiol Biomarkers Prev 12:226-7. 2003 - Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancerSusan K Murphy
Division of Gynecologic Oncology, Duke University Medical Center, Box 91012, Durham, NC 27708, USA
Mol Cancer Res 4:283-92. 2006..These data indicate that the epigenetic changes observed in these cancers at the imprint center may contribute to IGF2 overexpression in a novel mechanistic manner... - Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancerDeanna Teoh
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 122:467-72. 2011..To evaluate the costs and effectiveness of thromboprophylaxis strategies following laparotomy for ovarian cancer... - Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancerJoellen M Schildkraut
Comprehensive Cancer Center, Department of Community and Family Medicine, Duke University Medical Center, and Department of Statistical Science, Duke University, Durham, North Carolina, USA
Cancer Res 69:2349-57. 2009..This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region... - Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group studyAngeles Alvarez Secord
DUMC 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 106:221-32. 2007.... - Relationship between tamoxifen use and high risk endometrial cancer histologic typesAmy E Bland
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 112:150-4. 2009.... - Outcomes in surgical stage I uterine papillary serous carcinomaLaura J Havrilesky
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 105:677-82. 2007..The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine whether outcomes of women with surgical stage I UPSC differ with and without adjuvant therapy... - Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancerLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
Cancer 118:386-91. 2012..The objective of the current study was to construct a cost-utility model to compare these 2 regimens with the incorporation of prospectively collected quality-of-life (QoL) data... - Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotypeJason C Barnett
Division of Gynecologic Oncology Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 116:556-62. 2010..The objective of this study was to examine the clinicopathologic correlates of T-regulatory (T(reg)) cell infiltration in serous ovarian cancers and to define gene signatures associated with high T(reg)s... - Antidepressant medication use [corrected] and risk of ovarian cancerPatricia G Moorman
Cancer Prevention, Detection, and Control Research Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
Obstet Gynecol 105:725-30. 2005..The objective of this paper was to evaluate whether women with ovarian cancer were more likely to report past use of antidepressants than control women... - Anthropometric measurements and epithelial ovarian cancer risk in African-American and White womenCathrine Hoyo
Department of Community and Family Medicine, Duke University Medical Center, 2424 Erwin Rd, Hock Plaza, Ste 602, Durham, NC 27710, USA
Cancer Causes Control 16:955-63. 2005..0; 95% CI = 0.7-1.4). These findings support the hypothesis that obesity is an important risk factor of ovarian cancer among African-Americans and Whites and also suggest that height may be a risk factor specific to African-Americans... - Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancerAmy E Bondurant
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, 27708, USA
Gynecol Oncol 123:581-7. 2011.... - Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsDeanna Teoh
Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
Gynecol Oncol 121:187-92. 2011..To explore the activity of dasatinib alone and in combination with paclitaxel and carboplatin in ovarian cancer cells and to determine if dasatinib activity can be predicted based on evaluation of the SRC pathway... - Analgesic drug use and risk of ovarian cancerJoellen M Schildkraut
Duke Comprehensive Cancer Center, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, North Carolina 27710, USA
Epidemiology 17:104-7. 2006..Previous epidemiologic research suggests that analgesic use may reduce the risk of ovarian cancer, although results are not consistent... - Genomic signatures to guide the use of chemotherapeuticsAnil Potti
Duke Institute for Genome Sciences and Policy, Duke University, Box 3382, Durham, North Carolina 27710, USA
Nat Med 12:1294-300. 2006..The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies... - Menopausal hormones and risk of ovarian cancerPatricia G Moorman
Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
Am J Obstet Gynecol 193:76-82. 2005..The objective of this study was to determine if use of menopausal hormones was associated with ovarian cancer and if risk varied by type of hormone used... - Ovarian cancer risk factors in African-American and white womenPatricia G Moorman
Duke University Medical Center, 2424 Erwin Road, Suite 602, Durham, NC 27705, USA
Am J Epidemiol 170:598-606. 2009..There is a clear need for further research on etiologic factors for ovarian cancer in African-American women... - Evaluation of two management strategies for preoperative grade 1 endometrial cancerMarcus Q Bernardini
Division of Gynaecologic Oncology, University Health Network, Toronto, Ontario, Canada
Obstet Gynecol 114:7-15. 2009..To compare the practices, adjuvant treatment, and outcomes of patients with preoperatively assessed grade 1 endometrioid endometrial cancer between two academic gynecologic oncology centers that use different treatment strategies... - Robotic-assisted laparoscopic gynecologic procedures in a fellowship training programPaula S Lee
Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
JSLS 13:467-72. 2009..Our goal was to perform an early evaluation of the feasibility of training fellows in robotic-assisted gynecologic procedures at the outset of our incorporation of this technology into clinical practice... - Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinomaLouis A Dainty
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and the United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC 20307, USA
Gynecol Oncol 105:563-70. 2007..The purpose of this study was to examine the expression of FOLR1 in uterine cancers and to identify changes in gene expression that are associated with overexpression of FOLR1... - Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cellsGustavo C Rodriguez
Division of Gynecologic Oncology, NorthShore University Healthsystem, Evanston, IL 60201, USA
Am J Obstet Gynecol 206:253.e1-9. 2012..Because both induce apoptosis, we investigated the potential for synergistic impact of combined drug treatment on cell death... - Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controlsMarilyn F Vine
Cancer Prevention, Detection and Control Research Program, Box 2949, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 90:75-82. 2003..CONCLUSION: Earlier diagnosis of ovarian cancer may be possible if women and physicians recognize the importance of combinations of seemingly unrelated symptoms, especially those identified as occurring longer before diagnosis... - The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancerAngeles Alvarez Secord
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 94:74-9. 2004.... - Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)Patricia G Moorman
Cancer Prevention, Detection, and Control Research Program, Department of Community and Family Medicine, Duike Universiti Medical Center, Durham, NC 27710, USA
Cancer Causes Control 13:807-11. 2002..To compare two methods for calculating lifetime ovulatory cycles (LOC) to determine if more detailed menstrual cycle information results in stronger associations with ovarian cancer... - Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancerJonathan S Berek
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Women s Cancer Center, Stanford Cancer Center, Stanford, California, USA
Obstet Gynecol 116:733-43. 2010..Conversely, women at high risk of ovarian cancer should undergo risk-reducing bilateral salpingo-oophorectomy... - High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survivalJohnathan M Lancaster
Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27720, USA
Clin Cancer Res 9:762-6. 2003..We therefore sought to confirm the association between TRAIL expression and survival in a larger group of women with ovarian cancer... - High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancerZhiqing Huang
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27708, USA
Nucleic Acids Res 34:555-63. 2006..They further show that the methylation status of the intron 2 CpG island may be a useful indicator of LOH and biomarker of disease... - Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group StudyLaura Havrilesky
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA
J Clin Oncol 21:3814-25. 2003..The prognostic significance of p53 mutations and overexpression in advanced epithelial ovarian cancers was examined in primary tumors from 125 patients participating in a Gynecologic Oncology Group randomized phase III treatment protocol... - Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reductionLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 117:545-53. 2011..The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies... - High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancerJason C Barnett
Department of Obstetrics and Gynecology Division of Gynecologic Oncology and Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
Obstet Gynecol 115:49-54. 2010..To estimate the range of poly(adenosine diphosphate [ADP]-ribose) polymerase expression in serous ovarian cancers and to determine whether expression is associated with response to therapy and outcome... - Predictors of clinical outcomes in the laparoscopic management of adnexal massesLaura J Havrilesky
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
Obstet Gynecol 102:243-51. 2003..To a great extent, adverse events were attributable to concurrent hysterectomy rather than removal of the adnexal mass... - Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidityJohn T Soper
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
Gynecol Oncol 97:596-601. 2005..To compare flap-specific complications of rectus abdominis myocutaneous (RAM) and myoperitoneal (RAMP) flap neovagina reconstructions performed concurrently with radical pelvic procedures... - Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammationG Larry Maxwell
Division of Gynecologic Oncology, Walter Reed Army Medical Center, 6900 Georgia Avenue, Washington DC 20307, USA
Gynecol Oncol 121:586-94. 2011..The present study aimed to identify differentially expressed proteins employing a high resolution mass spectrometry (MS)-based proteomic analysis of endometrial cancer cells harvested using laser microdissection... - A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinomaEllen L Jones
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 98:277-82. 2003..The authors evaluated response and toxicity in patients with locally advanced cervical carcinoma (LACC) who were treated with concurrent weekly CDDP, HT, and RT (whole pelvis [n=7] and whole pelvis and paraaortic nodes [n=5])... - The role of PET scanning in the detection of recurrent cervical cancerLaura J Havrilesky
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 90:186-90. 2003..Little is known about the efficacy of PET for detecting recurrent disease. We evaluated the potential role of FDG PET in the context of suspected recurrent cervical cancer... - Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancerLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
Gynecol Oncol 88:51-7. 2003..Combination paclitaxel and carboplatin is a well-established first-line regimen for ovarian cancer. The purpose of this study was to evaluate weekly low-dose paclitaxel and carboplatin in recurrent ovarian or peritoneal cancer... - The role of genetic testing for cancer susceptibility in gynecologic practiceBeth Y Karlan
Women s Cancer Research Institute, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of Los Angeles, Los Angeles, California 90048, USA
Obstet Gynecol 110:155-67. 2007..Practical applications of genetic testing for cancer susceptibility have the ability to reduce the burden of hereditary cancers by saving lives, decreasing medical morbidities, and reducing psychological stress... - Molecular aspects of ovarian cancerRobert M Wenham
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Best Pract Res Clin Obstet Gynaecol 16:483-97. 2002..Hopefully, this knowledge can be translated into effective screening, treatment, surveillance, and prevention strategies in the future... - Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-betaGustavo C Rodriguez
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
J Natl Cancer Inst 94:50-60. 2002..We determined the effect of progestin on TGF-beta expression in the primate ovarian epithelium and examined the relationship between TGF-beta expression and apoptosis... - Consortium analysis of 7 candidate SNPs for ovarian cancerSusan J Ramus
Translational Research Laboratory, University College London EGA Institute for Women s Health, London, United Kingdom
Int J Cancer 123:380-8. 2008..These null results for SNPs identified from relatively large initial studies shows the importance of replicating associations by a consortium approach... - Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancerG Larry Maxwell
Division of Gynecologic Oncology/Walter Reed Army Medical Center, Washington, DC 20307, USA
Clin Cancer Res 11:4056-66. 2005..An understanding of the molecular heterogeneity of various histologic types of endometrial cancer has the potential to lead to better individualization of treatment in the future... - BRAF polymorphisms and the risk of ovarian cancer of low malignant potentialLivia Kelemen
Queensland Institute of Medical Research, 300 Herston Rd, Herston, QLD 4006, Australia
Gynecol Oncol 97:807-12. 2005..6%. We therefore hypothesized that the same BRAF haplotype may confer an increased risk of serous ovarian tumors of low malignant potential... - High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancerRobyn A Sayer
H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MCC-GYNPROG, Tampa, FL 33612-9497, USA
Gynecol Oncol 96:355-61. 2005..As such, IGF-2 is a molecular marker and potential therapeutic target for the most aggressive epithelial ovarian cancers... - Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributionsSteven J Skates
Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, USA
J Clin Oncol 22:4059-66. 2004..For direct comparisons between marker panels, all sensitivity results correspond to a 98% fixed first-line specificity (referral rate 2%)... - Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancerZhen Zhang
Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Cancer Res 64:5882-90. 2004..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer... - Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysisKaren H Lu
Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:3291-300. 2004..CONCLUSIONS: Our data are consistent with the possibility that a limited number of markers in combination might identify >99% of epithelial ovarian cancers despite the heterogeneity of the disease... - Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancerJanos L Tanyi
Departments of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:3534-45. 2003..Thus, the LPA-rich environment of the ovarian cancer cell in vivo and the subsequent effects of cellular pathophysiology may be a consequence of both increased LPA production and decreased LPA metabolism by ovarian cancer cells... - Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signalingJohn I Risinger
Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland, USA
Cancer Res 65:5031-7. 2005..These data classify histologically similar endometrioid endometrial cancers into two distinct groupings with implications affecting therapy and prevention... - Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarrayMichael A Bidus
Walter Reed Army Medical Center and the United States Military Cancer Institute, Washington, DC 20307, USA
Clin Cancer Res 12:83-8. 2006..Future studies should address whether the status of nodal metastasis can be determined from the expression profiles of preoperative tissue specimens... - Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histologyChristopher V Lutman
Riverside Gynecologic Oncology, Columbus, OH 43214, USA
Gynecol Oncol 102:92-7. 2006..Most likely, the association of survival and lymph node count in this group is the result of improved staging among patients with higher pelvic lymph node counts... - Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instabilityJohn I Risinger
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Biomark 2:61-8. 2006..These data indicate that significant differences in TIL derived transcripts do not occur between endometrioid endometrial cancers with and without microsatellite instability... - An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancerHolly K Dressman
Division of Gynecologic Surgical Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
J Clin Oncol 25:517-25. 2007..We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease... - Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expressionJohn Ian Risinger
Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Clin Cancer Res 13:1713-9. 2007..The purpose of this study was to identify those CT genes with the greatest incidence of expression in uterine cancers... - Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancerSimon A Gayther
Translational Research Laboratories, University College London, London, United Kingdom
Cancer Res 67:3027-35. 2007..This study highlights the need for multicenter collaborations for genetic association studies... - Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colonRebecca T Marquez
Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 11:6116-26. 2005..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble... - Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancerZhen Zhang
Center for Biomarker Discovery, Department of Pathology, Johns Hopkins Medical Institutions, CRB II 3M04, 1550 Orleans Street, Baltimore, MD 21231, USA
Gynecol Oncol 107:526-31. 2007..In this paper, an ANN model was evaluated for its performance in detecting early stage epithelial ovarian cancer using multiple serum markers... - Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositionsJohnathan M Lancaster
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Gynecol Oncol 107:159-62. 2007..This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome... - Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancerJohn I Risinger
Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Res 63:6-11. 2003..These data provide the basis for investigation of previously unrecognized novel pathways involved in the development of endometrial cancers...
Research Grants
- Society of Gynecologic Investigation Annual MeetingAndrew Berchuck; Fiscal Year: 2007..It is hoped that this initiative will stimulate greater interest in cancer research by those early in their careers, and will enhance the scientific exchange and collaboration of more senior investigators. ..